{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T02:53:53Z","timestamp":1764557633676},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,17]]},"DOI":"10.7759\/cureus.23262","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T15:07:04Z","timestamp":1647529624000},"source":"Crossref","is-referenced-by-count":3,"title":["An Unusual Presentation of Extramedullary Relapse Following Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia"],"prefix":"10.7759","author":[{"given":"Sanae","family":"Daghri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounia","family":"Bendari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Belmoufid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anass","family":"Yahyaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryame","family":"Ahnach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-242750","article-title":"How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"116","author":"Fielding AK","year":"2010","unstructured":"Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010, 116:3409-17. 10.1182\/blood-2010-01-242750","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.018","article-title":"Isolated extramedullary relapse as a poor predictor of survival after allogeneic hematopoietic cell transplantation for acute leukemia","volume":"25","author":"Sakellari I","year":"2019","unstructured":"Sakellari I, Gavriilaki E, Batsis I, et al.. Isolated extramedullary relapse as a poor predictor of survival after allogeneic hematopoietic cell transplantation for acute leukemia. Biol Blood Marrow Transplant. 2019, 25:1756-60. 10.1016\/j.bbmt.2019.05.018","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.023","article-title":"Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse","volume":"23","author":"Shem-Tov N","year":"2017","unstructured":"Shem-Tov N, Saraceni F, Danylesko I, Shouval R, Yerushalmi R, Nagler A, Shimoni A. Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse. Biol Blood Marrow Transplant. 2017, 23:1087-94. 10.1016\/j.bbmt.2017.03.023","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp MS","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, et al.. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014, 32:4134-40. 10.1200\/JCO.2014.56.3247","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger M","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, et al.. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012, 119:6226-33. 10.1182\/blood-2012-01-400515","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp MS","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, et al.. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015, 16:57-66. 10.1016\/S1470-2045(14)71170-2","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al.. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017, 376:836-47. 10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-834911","article-title":"Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab","volume":"131","author":"Aldoss I","year":"2018","unstructured":"Aldoss I, Song JY. Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab. Blood. 2018, 131:2507. 10.1182\/blood-2018-02-834911","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss I","year":"2017","unstructured":"Aldoss I, Song J, Stiller T, et al.. Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol. 2017, 92:858-65. 10.1002\/ajh.24783","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2018.04.006","article-title":"Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment","volume":"43","author":"Demosthenous C","year":"2019","unstructured":"Demosthenous C, Lalayanni C, Iskas M, Douka V, Pastelli N, Anagnostopoulos A. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment. Curr Probl Cancer. 2019, 43:222-7. 10.1016\/j.currproblcancer.2018.04.006","journal-title":"Curr Probl Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33967","article-title":"Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia","volume":"128","author":"Aldoss I","year":"2022","unstructured":"Aldoss I, Otoukesh S, Zhang J, et al.. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2022, 128:529-35. 10.1002\/cncr.33967","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220934853","article-title":"Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab","volume":"27","author":"Lau KM","year":"2021","unstructured":"Lau KM, Saunders IM, Goodman AM. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab. J Oncol Pharm Pract. 2021, 27:821-6. 10.1177\/1078155220934853","journal-title":"J Oncol Pharm Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.14176","article-title":"B-cell lymphoblastic lymphoma of unilateral primary breast mass in a boy aged 11 years","volume":"27","author":"Oral H","year":"2021","unstructured":"Oral H, Turkyilmaz Z, Arslan Kahraman D\u0130, Kaya C, Karabulut R, Tart\u0131k A, S\u00f6nmez K. B-cell lymphoblastic lymphoma of unilateral primary breast mass in a boy aged 11 years. Breast J. 2021, 27:271-2. 10.1111\/tbj.14176","journal-title":"Breast J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04199-9","article-title":"Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia","volume":"99","author":"Yu J","year":"2020","unstructured":"Yu J, Ge X, Luo Y, et al.. Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia. Ann Hematol. 2020, 99:2639-48. 10.1007\/s00277-020-04199-9","journal-title":"Ann Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.306","article-title":"Blinatumomab retreatment after relapse in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp MS","year":"2018","unstructured":"Topp MS, Stelljes M, Zugmaier G, et al.. Blinatumomab retreatment after relapse in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia. Leukemia. 2018, 32:562-5. 10.1038\/leu.2017.306","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2019.12.001","article-title":"Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia","volume":"68","author":"Danylesko I","year":"2020","unstructured":"Danylesko I, Chowers G, Shouval R, et al.. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Curr Res Transl Med. 2020, 68:17-22. 10.1016\/j.retram.2019.12.001","journal-title":"Curr Res Transl Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/88828-an-unusual-presentation-of-extramedullary-relapse-following-blinatumomab-in-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:12Z","timestamp":1707507312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/88828-an-unusual-presentation-of-extramedullary-relapse-following-blinatumomab-in-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.23262","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,17]]}}}